Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03841721 Active, not recruiting - Healthy Clinical Trials

Linezolid in Healthy Volunteers

Start date: May 1, 2018
Phase: Phase 1
Study type: Interventional

Linezolid is the first synthetic antibiotic of oxazolidinone group that can inhibit bacterial protein synthesis. Previous studies have found that linezolid was an effective treatment for multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). In addition, the current dosage recommendation (1,200 mg/day) occasionally resulted in serious adverse events including bone marrow suppression and peripheral neuropathy. The objective study were determine the pharmacokinetics of oral linezolid 300 mg /day in healthy volunteers. This study conducted in six healthy volunteers. All subject received an oral linezolid 300 mg/day by directly observed treatment (DOT) at the same time each day for 5 days. Blood samples were collected on day 5 at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 h post dosing. The separated plasma samples were evaluated by ultra-performance liquid chromatography (UPLC). All pharmacokinetic parameters were calculated.

NCT ID: NCT03804671 Active, not recruiting - Healthy Clinical Trials

A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet

Start date: January 31, 2019
Phase: Phase 1
Study type: Interventional

To investigate the absolute oral bioavailability of BI 730357 administered as tablet compared with [C-14]BI 730357 BS administered as intravenous microtracer

NCT ID: NCT03795441 Active, not recruiting - Healthy Clinical Trials

A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults

Start date: January 7, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the shedding and kinetics of the Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) vaccine after one intramuscular injection of Ad26.RSV.preF in adults.

NCT ID: NCT03784196 Active, not recruiting - Healthy Clinical Trials

Changes of Pain Sensitivity During Rehabilitation of Patients Suffering From Whiplash Associated Disorders

Start date: May 16, 2016
Phase:
Study type: Observational [Patient Registry]

This study investigates the sensory profile of people suffering from whiplash associated disorders (WAD) during rehabilitation.

NCT ID: NCT03760848 Active, not recruiting - Healthy Clinical Trials

Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Aramchol in Healthy Volunteers

Start date: November 12, 2018
Phase: Phase 1
Study type: Interventional

The trial is an open-label, 2-period, single-sequence assessment of CYP3A4 inhibition by aramchol using the probe substrates midazolam and atorvastatin to assess CYP3A4 activity.

NCT ID: NCT03744091 Active, not recruiting - Healthy Clinical Trials

Evaluation of the Pharmacokinetics of Prana P1 Capsules

Start date: July 16, 2018
Phase: Phase 1
Study type: Interventional

This is a single dose clinical trial to assess the Pharmacokinetics of two (2) dosages; 10 mg and 20mg of THC: THCa of Prana P1 bionutrients in healthy volunteers.

NCT ID: NCT03736980 Active, not recruiting - Healthy Clinical Trials

Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the Self

Start date: October 1, 2013
Phase: N/A
Study type: Interventional

The aim of the study is to identify neural signatures, behavioral and phenomenological expressions of self-related processes including: sense of agency, semantic distinction between self and other, selflessness (altruism), social agency, embodied self (interoception), perceptual functioning of dissolved self including hallucinations and crossmodal processing, and finally the mystical type dissolution of the self.

NCT ID: NCT03736772 Active, not recruiting - Healthy Clinical Trials

A Study of LY3090106 in Japanese and Caucasian Healthy Participants

Start date: November 19, 2018
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety of a study drug known as LY3090106 in healthy Caucasian and Japanese participants. Side effects and tolerability will be documented. Blood samples will be taken to compare how the body handles the drug. The study will last about 12 weeks, not including screening or additional follow-up.

NCT ID: NCT03725462 Active, not recruiting - Healthy Clinical Trials

Evaluation of Electrophysiological Signal Measured by Smart Textile CE-marked

STREAM
Start date: October 16, 2017
Phase: N/A
Study type: Interventional

The aim is to evaluate the performance of Cardioskin and Neuronaute, two connected medical devices CE-marked, manufactured by Bioserenity. It's an open monocentric comparative clinical study, where subjects will test the Cardioskin device and/or the Neuronaute device.

NCT ID: NCT03712761 Active, not recruiting - Healthy Clinical Trials

Supplementation of a Leucine-Enriched Dairy Protein Blend

Start date: March 28, 2018
Phase:
Study type: Observational

It is well known that dietary protein is a powerful transient stimulator of the muscle protein synthetic rate (MPS) whereby changes in MPS in response to feeding may be regulated by specific downstream target proteins of mammalian target of rapamycin signaling, such as S6K1, rpS6, and eIF2B. A meal deficient in protein, however, does not increase the rate of MPS because a rise in the bioavailability of amino acids does not occur. In addition, the source of dietary proteins has been shown to impact postprandial blood levels of amino acids. The concept that certain types of proteins are "fast acting" or "slow acting" has been shown to affect the postprandial profile of amino acids appearing in the systemic circulation. Native whey and micellar casein are both dairy proteins that contain a similar amount of essential (EAA), but blood EAA levels increase faster and to a higher level after the consumption of whey protein. Differences in gastric emptying, digestion and absorption kinetics between micellar casein and native whey are the underlying factors. Nonetheless, micellar casein protein has been shown to protract MPS in humans. Despite the significant amount of information gained with respect to both of these protein sources, the effects of combinatorial formulations on the postprandial profile of amino acids appearing in the blood is less well known. The purpose of the present study is to determine post-ingestion aminoacidemia, glycemia, and insulinemia from a specially formulated dairy protein blend.